Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:NBTX

Nanobiotix Q4 2025 Earnings Report

Nanobiotix logo
$27.64 -3.52 (-11.28%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanobiotix EPS Results

Actual EPS
-$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
$3.42 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanobiotix Announcement Details

Quarter
Q4 2025
Date
2/15/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanobiotix Earnings Headlines

Nanobiotix (NASDAQ:NBTX) Shares Down 4.3% - Time to Sell?
October 1 at 7:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073939
HC Wainwright Decreases Earnings Estimates for Nanobiotix
September 29 at 6:42 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063708
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
October 1 at 1:00 AM  |  Profits Run (Ad)
Can J&J’s Partnership Drive More Upside for Nanobiotix?
September 28 at 6:36 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/can-jjs-partnership-drive-more-upside-for-nanobiotix-1845930/
Nanobiotix FY2027 Earnings Forecast Lowered by HC Wainwright
September 28 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056368
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368753/0/en/nanobiotix-provides-first-half-2026-operational-and-financial-update.html
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles. NBTXR3 is injected directly into a tumor and activated by standard radiotherapy. Nanobiotix has evaluated the candidate in several solid-tumor settings and is studying its potential for use in combination with other cancer treatments, including immunotherapies. NBTXR3 has not been approved for commercial use by regulatory authorities.

Founded in 2003, Nanobiotix is headquartered in Paris, France, and has conducted development activities and clinical studies in multiple geographic regions, including Europe, the United States and Asia. The company was co-founded by Laurent Levy, who has served as its chief executive officer and has led its development of nanoparticle-based oncology treatments.

View Nanobiotix Profile
Earnings Tools